Clinical trial · Observational
Renal Cancer Detection With Liquid Biopsy
NCT05060783CI-TRIAL-00073417GaGnosticrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncocytoma | Oncocytic Neoplasm | ALIAS | 0.90 |
| Renal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GaGnostic | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Renal Call Carcinoma
- description
- Patrients with renal cancer
- interventionNames
- Diagnostic Test: GaGnostic
- label
- Oncocytoma
- description
- Patients with oncocytoma
- interventionNames
- Diagnostic Test: GaGnostic
- label
- Healthy persons
- description
- Patients with CT scan shows no renal cancer
- interventionNames
- Diagnostic Test: GaGnostic
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer. 2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen) 3. Sign up information consent 4. Can perform protocol procedure Exclusion Criteria: 1. Non-clear cell Renal cell carcinoma 2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney 3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
References
Publications (0)
Data not yet available
No reference posted for this study.